Levetiracetam prevents Aβ production through SV2a-dependent modulation of APP processing in Alzheimer's disease models - PubMed
3 months ago
- #Alzheimer's disease
- #Amyloid-β
- #Levetiracetam
- Levetiracetam (Lev) reduces Aβ42 levels by modulating amyloidogenic APP processing in an SV2a-dependent manner.
- Lev modifies synaptic vesicle (SV) cycling, increasing APP cell surface expression and promoting nonamyloidogenic processing.
- In mouse models, Lev restores SV cycling abnormalities, reduces synapse loss, and prevents Aβ42 production.
- Early Aβ pathology in Down syndrome brains shows elevated presynaptic proteins, suggesting a presynaptic role in Aβ accumulation.
- The findings suggest potential for early intervention to prevent Aβ pathology before irreversible damage occurs.